Impacts of human and bacterial natural genomic diversity on cholera disease severity
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:0 publications
Grant number: 434104
Grant search
Key facts
Disease
Cholerastart year
2020Known Financial Commitments (USD)
$545,826.52Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
Shapiro JesseResearch Location
050Lead Research Institution
McGill UniversityResearch Priority Alignment
N/A
Research Category
Epidemiological studies
Research Subcategory
Disease susceptibility
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Cholera is a diarrheal disease caused by the waterborne bacterium Vibrio cholerae that has caused devastating pandemics and mortality throughout human history. Today, cholera causes over 100,000 deaths every year. Despite extensive study, it is still difficult to predict cholera outbreaks or virulence within individuals. Cholera vaccines exist, but are less than 60% effective, and do not confer long-term immunity. Remarkably, some people exposed to V. cholerae do not become ill and instead become asymptomatic carriers, capable of transmitting the infection. My team will study cholera patients and their household contacts in Bangladesh, where cholera is endemic. Cholera patients are treated by doctors, and most recover. Their contacts have a high risk (~20%) of being infected with V. cholerae, and ~75% of those infected go on to develop symptomatic cholera. By prospectively sampling both cholera patients and their at-risk contacts, we can follow the transition from asymptomatic to symptomatic cholera and identify risk factors. The risk factors measured in our study include mutations in the human or V. cholerae genome, human immune responses, and potentially protective bacteria in the gut microbiome. V. cholerae mutations can occur during an infection, and may help V. cholerae evade the human immune system, or allow it to cause more severe disease. However, even if mutations can benefit V. cholerae on the short term (within one patient), they might be "evolutionary dead-ends" if they hinder its ability to transmit to new patients. Our study will allow us to identify such dead-ends, which could eventually be exploited to reduce cholera transmission. V. cholerae mutations associated with desired outcomes (e.g. strong immune responses, less severe disease and less transmission) could eventually be used in new vaccines.